The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study

• Published in: The journal of clinical psychiatry Vol. 78; no. 9; p. 1344
• Main Authors: Factor, Stewart A, Remington, Gary, Comella, Cynthia L, Correll, Christoph U, Burke, Joshua, Jimenez, Roland, Liang, Grace S, O'Brien, Christopher F
• Format: Journal Article
• Language: English
• Published: United States 01.11.2017

Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia. Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a moo...